Anagliptin, A Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients - Concepedia

Concepedia

Publication | Closed Access

Anagliptin, A Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients

23

Citations

0

References

2016

Year

Nobuhiro Tahara, Sho‐ichi Yamagishi, Munehisa Bekki, Norihiro Kodama, Tomohisa Nakamura, Yoichi Sugiyama, Tamami Oshige, Yuki Kumashiro, Akihiro Honda, Atsuko Tahara,

Current Vascular Pharmacology

Abstract

The present study suggests that anagliptin may exert a beneficial effect on arterial stiffness in patients with T2DM, which is independent of its blood glucose-lowering property. Anagliptin may ameliorate arterial stiffness partly via reduction of RLP cholesterol and improvement of liver function.